EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Disease‐modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications

Erika L Hellenbart iD, Heather J Ipema iD, Mary C Rodriguez-Ziccardi iD, Hema Krishna iD, Robert J DiDomenico iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-02 · 45 (2) · 124-144

DOI: 10.1002/phar.4639 ↗

At a glance

Übersichtsarbeit in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2024-12-23. Written by Erika L Hellenbart and 4 co-authors. Institution: Department of Pharmacy Practice, University of Illinois Chicago, Chicago, Illinois, USA. Major MEDLINE topics: Amyloid Neuropathies, Familial, Cardiomyopathies. Cited 19 times so far (Crossref); 123 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Transthyretin amyloidosis (ATTR) is a rare disease that results in amyloid fibril misfolding and deposition in multiple organs, including the heart, leading to the development of ATTR cardiomyopathy (ATTR‐CM), which is associated with poor outcomes. In the last decade, several disease‐modifying medications are in advanced stages of clinical development or have been approved to treat ATTR‐CM. The purpose of this review is to critically evaluate clinical trial data investigating the use of approved and investigational medications for the treatment of ATTR‐CM. We performed a comprehensive literature search via PubMed and EMBASE to identify randomized controlled trials evaluating medications for the treatment of ATTR‐CM published through August 2024. This narrative review describes the pathophysiology of ATTR‐CM, highlights important screening and diagnostic work‐up, and summarizes the existing clinical evidence resulting from our literature search. Several classes of disease‐modifying medications are in development for ATTR‐CM. The tetramer stabilizers and transthyretin silencers have proven to be the most effective therapies to date. Tafamidis and acoramidis are currently approved for ATTR‐CM while vutrisiran approval for ATTR‐CM may be forthcoming. Other disease‐modifying medication classes in development include antisense oligonucleotides, gene editing therapies, and monoclonal antibodies. However, several unmet needs exist including the lack of cost‐effectiveness due to the extremely high acquisition costs of these medications. Disease‐modifying medications approved and in development to treat ATTR‐CM offer hope for patients with this disease, but their lack of affordability is the biggest barrier to their use.

Subjects

MeSH terms (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesHumansPrealbuminBenzoxazoles

Author keywords

RNAamyloidosisantisensecardiomyopathieseplontersenhumanoligonucleotidespatisiransmall interferingtafamidistransthyretin‐related amyloid fibril protein

Substances

PrealbumintafamidisBenzoxazoles

Authors and institutions

  • Department of Pharmacy Practice, University of Illinois Chicago, Chicago, Illinois, USA.
  • Department of Medicine, Section of Cardiology, University of Illinois Chicago, Chicago, Illinois, USA.
  • Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois Chicago, Chicago, Illinois, USA.

ORCID profiles: Erika L Hellenbart, Heather J Ipema, Mary C Rodriguez-Ziccardi, Hema Krishna, Robert J DiDomenico

Cite

APA

Hellenbart, E. L., Ipema, H. J., Rodriguez-Ziccardi, M. C., Krishna, H., & DiDomenico, R. J. (2025). Disease‐modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 45(2), 124-144. https://doi.org/10.1002/phar.4639

Vancouver

Hellenbart EL, Ipema HJ, Rodriguez-Ziccardi MC, Krishna H, DiDomenico RJ. Disease‐modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025;45(2):124-144. doi:10.1002/phar.4639

BibTeX
@article{Hellenbart2025,
  author = {Hellenbart, Erika L and Ipema, Heather J and Rodriguez-Ziccardi, Mary C and Krishna, Hema and DiDomenico, Robert J},
  title = {Disease‐modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  volume = {45},
  number = {2},
  pages = {124--144},
  doi = {10.1002/phar.4639}
}
Start for free →